Protocol Ledger

NCT03677648 · Phase II · COMPLETED

A Phase II Study in Patients With Moderate to Severe Active Crohn's Disease

Interventional Phase II clinical trial protocol NCT03677648 sponsored by Reistone Biopharma Company Limited in Immunology, Rheumatology, and Dermatology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2019-05-14 Enrollment: 112 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT03677648
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)112 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03677648
Protocol FieldVerified Registry Value
NCT IdentifierNCT03677648
Consolidated Lead SponsorReistone Biopharma Company Limited
Therapeutic Condition CohortImmunology, Rheumatology, and Dermatology
Clinical Trial PhasePhase II
Overall Recruitment StatusCOMPLETED
Registered Enrollment112 participants (ACTUAL)
Registered Start Date2019-05-14
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Immunology, Rheumatology, and Dermatology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI